{ "case_number": "CAC-UDRP-104971", "time_of_filling": "2022-11-04 09:47:05", "domain_names": [ "novartis-bio.info " ], "case_administrator": "Denisa Bilík (CAC) (Case admin)", "complainant": [ "Novartis AG " ], "complainant_representative": "BRANDIT GmbH", "respondent": [ "PIERRE MARIONE" ], "respondent_representative": null, "factual_background": "

The Complainant owns numerous domain names composed of its trademark NOVARTIS alone, including (registered in 1996) or in combination with other terms, such as (registered in 1999).<\/no><\/no><\/p>\n

\n

The Complainant uses these domain names to resolve to its official websites through which it informs Internet users and potential consumers about its NOVARTIS mark and its related products and services.  <\/no><\/no><\/p>\n

The Complainant also enjoys a strong presence online via its official social media platforms.<\/no><\/no><\/p>\n

The Disputed Domain Name <novartis-bio.info> was registered by the Respondent on 24 October 2019. <\/p>\n<\/div>", "other_legal_proceedings": "

The Panel is not aware of any other legal proceedings which are pending or decided and which relate to the Disputed Domain Name.<\/p>", "no_response_filed": "

NO ADMINISTRATIVELY COMPLIANT RESPONSE HAS BEEN FILED.<\/p>\n

COMPLAINANT'S CONTENTIONS: <\/p>\n

(i) The Disputed Domain Name is identical or confusingly similar to a trademark or service mark in which the Complainant has rights; <\/p>\n

The Complainant owns numerous trademarks NOVARTIS registered in numerous jurisdictions. <\/span>The Disputed Domain Name <<\/span>novartis-bio.info> incorporates in its second-level portion entirely the Complainant’s registered trademark NOVARTIS along with the term “bio”, closely connected to the Complainant’s business and activities of the Complainant in the world. <\/span>The NOVARTIS trademark is clearly recognizable within the Disputed Domain Name while <\/span>the mere addition of a descriptive term would not prevent a finding of confusing similarity to a trademark. The presence of the generic Top-Level Domain (“gTLD”) extension “.info” in the first level portion of the Disputed Domain Name is a standard registration requirement and may be disregarded when assessing whether the Disputed Domain Name is confusingly similar to the trademark in which the Complainant has rights.<\/span><\/p>\n

The Disputed Domain Name is therefore confusingly similar to the Complainant’s NOVARTIS trademark. <\/span> <\/span><\/p>\n

(ii) The Respondent has no rights or legitimate interests in respect of the Disputed Domain Name<\/span><\/p>\n

The Complainant and the Respondent have never had any previous relationships, nor has the Complainant ever granted the Respondent with any rights to use the NOVARTIS trademark in any forms, including the Disputed Domain Name.<\/span> <\/span>The Complainant has not found that the Respondent is commonly known by the Disputed Domain Name or that it has legitimate interests over the Disputed Domain Name. When searched for “<\/span>novartis-bio” or “novartis-bio.info” in the Google search engine with or without Respondent’s name “Pierre Marione”, the search results point to the Complainant as well as another domain name dispute concerning the domain name novartis-bio.eu raised by the Complainant against the Respondent. The Respondent should have already performed a similar search before registering the Disputed Domain Name and should have quickly learnt that the trademarks are owned by the Complainant and that the Complainant has been using its trademarks in many other countries worldwide – in fact, evidence showed that the Respondent obviously knew about the Complainant and its trademark NOVARTIS when it registered the Disputed Domain Name. However, the Respondent still chose to register the Disputed Domain Name as such. <\/span> <\/span><\/p>\n

The Complainant noticed that the website associated to the Disputed Domain Name displays content displaying NOVARTIS trademark and logo in prominent position with the text “Product Validation” and a field “Enter Code” with the message “Please Enter Security Code” and the button “send”. Moreover, the also has different fields including “Somatropin Human Growth Hormone” which is manufactured by the Complainant<\/span>. <\/span>The website associated with the Disputed Domain Name <\/span>info@novartis-bio.eu<\/a> and other fields such as “About Us”, “Partnership” and others which do not resolve to any content but lead to error page when clicking on the same<\/span>. T<\/span>he website associated with the Disputed Domain Name <\/span>“NOVARTIS-BIO does not sell any pharmaceutical products online. We do not sell to the public. We do not ship any products. We are not directly or indirectly associated with any websites that may engage in selling same or similar products. Information contained within this website is not a prescription to use and is intended for INFORMATION purposes only”. <\/span>There is no information or statement about the absence of any relationship between the Complainant and the Respondent and the Respondent’s website. Considering the content of the web-site that impersonates the Complainant by displaying the logo in the prominent position as well as including the contact information as “Novartis – Bio, Switzerland EU” it is clear that the consumers might be easily mislead into believing that the website associated with the Disputed Domain Name is controlled by the Complainant. T<\/span>he Complainant filed an abuse report to the hosting provider in order to remove the misleading content. The Website has been removed on 28 October 2022<\/span>. By the time of filing of this complaint the content had not been removed. T<\/span>he Complainant has also filed the complaint regarding the disputed domain name <<\/span>bio-novartis.eu> (the e-mail associated to the mentioned domain name is displayed at the website associated to the Disputed Domain Name in the contact field)<\/span> <\/span><\/b>before Czech Arbitration Court. The holder of the domain name was not active in the mentioned proceedings and also the contact details of the Respondent differ, and namely, the Respondent in the .eu proceedings was disclosed as: <\/span>PIERRE MARIONE, Address: 99 ,Rue du Pr&eacute,sident &Eacute,douard Herriot, Lyon, 7740, France<\/span>. It therefore seems that the respondent provides inaccurate WHOIS data. The decision was rendered in favor of the Complainant<\/span>. T<\/span>he Respondent has been impersonating the Complainant and has been trying to mislead internet user into believing that the Website was authorized by \/ associated with the Complainant. The Respondent has not been using the Disputed Domain Name for any bona fide offering of goods or services.<\/span> <\/span><\/p>\n

(iii) The Disputed Domain Name<\/span> was registered and is being used in bad faith. <\/p>\n

1. Registration of the Disputed Domain Name<\/span> in bad faith <\/p>\n

The registration of the Complainant’s trademarks pre-dates the registration of the Disputed Domain Name and the Respondent has never been authorized by the Complainant to use the NOVARTIS trademark nor to register the Disputed Domain Name. The Respondent has chosen to incorporate the distinctive trademark NOVARTIS in the Disputed Domain Name in its entirety.<\/span> T<\/span>he Complainant enjoys a strong online presence. By conducting a simple online search regarding the terms “novartis-bio”<\/span>, the Respondent would have inevitably learnt about the Complainant, its trademark and business.<\/span> <\/span>It is therefore inconceivable that the Respondent was unaware of the existence of the Complainant when it registered the Disputed Domain Name.<\/span> <\/span>It is very likely that the Respondent registered the Disputed Domain Name incorporating the trademark NOVARTIS intentionally in order to take advantage of reputation of the trademark NOVARTIS and the Complainant’s goodwill.<\/span> <\/span><\/p>\n

2. The Disputed Domain Name<\/span> is being used in bad faith  <\/p>\n

The Disputed Domain Name along with the relevant term “bio” directly referring to the business of the Complainant being one of the leading pharmaceutical companies in the world.<\/span> T<\/span>he Respondent has used <\/span>the Complainant’s trademark NOVARTIS on the Website without any authorization from the Complainant, moreover the Respondent also displays “Novartis-Bio, Switzerland EU” as the contact name. B<\/span>y using the Disputed Domain Name, the Respondent has intentionally attempted to attract, for commercial gain, Internet users to its website, by creating a likelihood of confusion with the Complainant’s mark as to the source, sponsorship, affiliation, or endorsement of the Respondent’s website. A<\/span>ccording to the Registrar Verification, the Respondent appears as PIERRE MARIONE, 8 Mersinies, Tochn, Cyprus. At the same time, in the proceedings against <<\/span>novartis-bio.eu> domain name, the Respondent under the same name has different address and country of Residence. It therefore seems that the Respondent provides false WHOIS data. <\/span> <\/span><\/p>\n

It shall be concluded that the Complainant registered and used the Disputed Domain Name in bad faith and its conduct falls within the meaning of Paragraph 4(a)(iii) of the Policy.<\/span> <\/span><\/p>", "rights": "

The Complainant has, to the satisfaction of the Panel, shown the Disputed Domain Name is confusingly similar to a trademark or service mark in which the Complainant has rights (within the meaning of paragraph 4(a)(i) of the Policy).<\/p>", "no_rights_or_legitimate_interests": "

The Complainant has, to the satisfaction of the Panel, shown the Respondent to have no rights or legitimate interests in respect of the Disputed Domain Name (within the meaning of paragraph 4(a)(ii) of the Policy).<\/p>", "bad_faith": "

The Complainant has, to the satisfaction of the Panel, shown the Disputed Domain Name has been registered and is being used in bad faith (within the meaning of paragraph 4(a)(iii) of the Policy).<\/p>", "procedural_factors": "

The Panel is satisfied that all procedural requirements under UDRP were met and there is no other reason why it would be inappropriate to provide a decision.<\/p>", "decision": "Accepted", "panelists": [ "Vojtěch Trapl" ], "date_of_panel_decision": "2022-12-13 00:00:00", "informal_english_translation": "

The Novartis Group is one of the biggest global pharmaceutical and healthcare groups in the world. It provides solutions to address the needs of patients worldwide by developing and delivering innovative medical treatments and drugs.<\/p>\n

Novartis AG (the Complainant) has its headquarter in Switzerland, that it created in 1996 through a merger of two other companies Ciba-Geigy and Sandoz, and is the holding company of the Novartis Group.<\/p>\n

Novartis’ products are sold in about 155 countries and reached nearly 769 million people globally in 2020. About 100,000 people of 142 nationalities work at Novartis around the world. The Novartis group produces and markets its products in many parts of the world including in Europe which is one of the principal markets for Novartis. The Complainant employs 45,000 employees in Europe and has 80 sites from R&D to manufacturing, to commercial.<\/p>\n

In Cyprus (where the Respondent seems to be located), the Complainant operates via its subsidiary Novartis Pharma Services Inc. (Nikosia).<\/p>\n

The Complainant is the owner of the well-known trademark NOVARTIS registered as both a word and device mark in several classes worldwide, including in Cyprus.<\/p>\n

The vast majority of the Complainant’s trademark registrations significantly predate the registration of the Disputed Domain Name.<\/p>\n

Namely, the Complainant’s trademark registrations applying to the present proceedings include the following earlier rights: <\/p>\n

<\/p>\n

EU Trademark: NOVARTIS <\/p>\n

Reg. no: 000304857 <\/p>\n

Reg. date: June 25, 1999 <\/p>\n

 <\/p>\n

International Trademark Registration: NOVARTIS <\/p>\n

Reg. no: 1349878 <\/p>\n

Reg. date: November 29, 2016 <\/p>\n

 <\/p>\n

International Trademark Registration: NOVARTIS <\/p>\n

Reg. no: 1544148 <\/p>\n

Reg. date: June 29, 2020 <\/p>\n

<\/span><\/p>\n

The above mentioned trademarks are a non-exhaustive list of the Complainant's trademarks in Europe.<\/p>\n

The NOVARTIS trademark is well-known (for instance see Novartis AG v. Amartya Sinha, Global Webs Link, Novartis RO, WIPO Case No. D2020-3203).<\/p>", "decision_domains": { "novartis-bio.info ": "TRANSFERRED" }, "panelist": null, "panellists_text": null }